Related coverage linked through entity extraction aliases.
Jul 03, 2026
ASH has published new clinical practice guidelines for frontline and relapsed/refractory ALL management in adolescents and young adults, endorsing pediatric-inspired regimens, asparaginase therapy, and immunotherapy over traditional chemotherapy.
Jul 01, 2026
The U.S. five-year cancer survival rate reached 70% in 2025, creating 18.6 million survivors. Health systems are expanding survivorship care using advanced practice providers and investing over $4 billion in oncology infrastructure to meet growing demand.
Jun 25, 2026
Alliance launches Phase III trial for stage I NSCLC immunotherapy; Allarity starts Phase 2 SCLC trial. Phase I NSCLC trial sites consolidate at top U.S. sites, prompting FDA representation concerns.
Jun 23, 2026
The bladder cancer therapeutics market is expanding with recent FDA approvals including INLEXZO for NMIBC and a KEYTRUDA-Padvev combination for MIBC, while the NMIBC market reached approximately USD 3 billion in 2025 across seven major markets. Ferring reported record revenues exceeding €2.5 billion in 2025, driven by Adstiladrin as its second major growth driver. A robust pipeline of emerging therapies is expected to further transform the market through 2036.
Jun 14, 2026
Patients with stage 4 lung, sarcoma, and gastro-oesophageal cancer describe their experiences with targeted therapies, chemotherapy, and immunotherapy, highlighting varying outcomes and financial challenges.
Jun 11, 2026
The global oncology drugs market is projected to grow at an 8-10% CAGR through 2035 as targeted therapies and immunotherapies gain share over chemotherapy. The radiopharmaceuticals market is expected to reach $21.8 billion by 2033, fueled by rising cancer incidence and expanding diagnostic and therapeutic applications. Innovations in drug delivery, including intranasal platforms for glioblastoma, are advancing neuro-oncology treatment options.
Jun 11, 2026
Long-term data from ASCO 2026 shows the personalized cancer vaccine Intismeran Autogene, combined with Keytruda, reduces recurrence or death risk by 49% in high-risk melanoma patients. Developed by MSD and Moderna, the vaccine uses AI to select neoantigens from a patient's tumor and mRNA technology to create a personalized treatment. The results signal a major advance for a field that had struggled for decades, spurring similar development efforts by other companies.
Jun 08, 2026
A new "expand and pull" treatment strategy combines long-acting interleukin-7 and oncolytic virus therapy to boost T cell response in glioblastoma. In mouse models, the combination improved cytotoxic T cell function and led to long-term tumor-free survival.
May 30, 2026
The phase III frontMIND trial showed that adding tafasitamab and lenalidomide to R-CHOP chemotherapy reduced the risk of progression by 25% in patients with high-risk B-cell lymphomas. The 3-year progression-free survival was 67.3% with the combination versus 60.7% with R-CHOP alone. A dual-targeted CD19/CD20 immunotherapy regimen has also been approved in Australia for relapsed follicular lymphoma.
May 26, 2026
The global radiopharmaceuticals market is projected to reach $12.8B–$21.8B by 2033–2036, driven by cancer therapy demand. Oncology accounts for over 50% of applications, Technetium-99m dominates radioisotopes, and Asia-Pacific leads growth.
May 24, 2026
Maharashtra will add immunotherapy and PET scans to its state health scheme and open 27 new cancer centres. Separately, the ICMR has issued national guidelines for lung cancer treatment including immunotherapy protocols, as MPs push for expanded access.
May 20, 2026
The FDA fast-tracked an inhalable gene therapy for advanced lung cancer after an early 11-patient trial showed tumour shrinkage in three patients and disease stabilization in five. Larger studies involving about 250 patients are underway.
May 19, 2026
MSD said sacituzumab tirumotecan improved overall survival and progression-free survival in the Phase III TroFuse-005 trial in endometrial cancer. The study also met its objective response rate endpoint.
May 18, 2026
A real-world analysis found BRAF V600E-mutated papillary thyroid cancer had a proinflammatory molecular profile, but no significant overall survival difference versus BRAF wild-type disease. Treatment choice among BRAF/MEK inhibitors, tyrosine kinase inhibitors, and immunotherapy was not associated with significant survival differences.
May 13, 2026
Tumour-infiltrating lymphocyte therapy has shown durable responses in refractory melanoma, including a 31.4% objective response rate in phase II data. The 2024 FDA approval of Lifileucel marked a milestone as regulators in other markets continue reviews.
May 11, 2026
A Nature Communications study reported that STING agonist 8803 inhibited tumor growth in human meningioma samples and reduced tumor volume and mortality in mouse models. Researchers found the STING pathway is expressed in both meningioma tumor cells and immune cells in the tumor microenvironment.
May 07, 2026
Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.
May 06, 2026
New therapies including CAR-T, bispecific antibodies and dual-antibody immunotherapy are reshaping multiple myeloma care. Advances in genomic testing may also improve risk assessment and treatment decisions.
May 01, 2026
Researchers identify DPY30 as an epigenetic target to sensitize pancreatic tumors to immunotherapy. UC San Diego researchers redirect CMV immunity against pancreatic cancer in preclinical models. A Fred Hutch researcher receives ACS grant to study immunotherapy resistance in melanoma.
Apr 30, 2026
Two studies show liquid biopsy can predict immunotherapy response in HER2-negative breast cancer and identify which patients with relapsed germ cell tumors may benefit from high-dose chemotherapy, advancing precision oncology.
